There are currently three ongoing clinical trials evaluating the use of an anti-B7-H3 antibody in combination with either anti-PD-1 or anti-CTLA-4 for advanced solid tumors, including NSCLC (NCT03729596; NCT02475213; NCT02381314) (189–191). Here, PDCD1 is linked to non-small cell lung carcinoma.